H HiPerformance CultureThe Evidence
Bio 5 min read
Trend Breakdown
The Evidence

Does methylene blue actually sharpen cognition?

Methylene blue entered biohacking on the back of a credible mitochondrial mechanism and high-profile endorsements. The mechanism is real; the human evidence is thin. One small healthy-adult RCT and a large negative Alzheimer's trial frame the limits, with a documented drug interaction that makes this supplement genuinely risky for some people.

Published 4 Jun 2026 · 5 sources
Skip to the verdict ↓
Trend Science
Breakdown
Evidence-graded series
02What's being claimed

Methylene blue is a mitochondrial optimiser that sharpens thinking, improves memory, and slows brain ageing. By cycling electrons directly through the mitochondrial electron transport chain, it raises neuronal ATP output. The mechanism is grounded in serious biochemistry, drawing on a pharmaceutical compound with over a century of clinical use.

The appeal of methylene blue has three roots. Neuroscientist Francisco Gonzalez-Lima at UT Austin published foundational animal and human studies framing it as a mitochondrial nootropic, lending academic credibility to a compound with over a century of pharmaceutical use 1. Then high-profile biohackers including Bryan Johnson and Robert F. Kennedy Jr. publicly endorsed it, followed by blue-tongue TikTok content that drove a sharp rise in US search interest for 'methylene blue benefits'.

Underlying this is a legitimate mechanistic claim. Methylene blue functions as a redox agent: it accepts electrons from NADH and donates them to cytochrome c oxidase (Complex IV), thereby bypassing dysfunctional upstream complexes and increasing ATP synthesis 1. In neural tissue, where energy demand is high, the theory holds that raising ATP availability should translate to improved cognitive function. The question is whether that chain of causation holds in healthy, non-impaired human brains.

Origin
1876 textile dye
Synthesised as an industrial dye in 1876; adopted as the first synthetic anti-malarial and methaemoglobinaemia treatment by 1891.
→
Vector
Gonzalez-Lima lab
UT Austin neuroscientist Francisco Gonzalez-Lima published foundational animal and human RCTs framing MB as a mitochondrial nootropic.
→
Spike
Biohacking influencers
Bryan Johnson and RFK Jr. endorsements drove a sharp rise in US searches for 'methylene blue benefits'.
"I've been taking low-dose methylene blue every morning for three months. The mental clarity is unlike anything else I've tried. The science on mitochondrial function is rock solid. This is next-level biohacking."
— Representative of the claim as it circulates in biohacking communities
03The evidence verdict
H
HiPerformance Culture The Evidence · Trend Breakdown
Verdict

Plausible mechanism, thin human evidence, genuine serotonin toxicity risk for anyone on SSRIs.

Hype Evidence
This trend lands here
Low Moderate High
Low confidence 5 sources cited · 1 comprehensive review, 2 RCTs, 1 phase 3 trial, 1 safety review · 2010–2021
✓

What holds up

✓
Methylene blue cycles electrons at mitochondrial Complex IV, increasing ATP output in neural tissue; confirmed consistently in vitro and in animal models 1.
Gold
✓
A double-blind RCT (n=26) found low-dose MB improved memory retrieval by approximately 7% versus placebo, with increased prefrontal and insular cortex fMRI activity 2.
Silver
✓
IV methylene blue (2 mg/kg) reduced postoperative delirium from 24.2% to 7.3% and early cognitive dysfunction from 40.2% to 16.1% in a 248-patient RCT of elderly surgical patients 5.
Silver
✕

What doesn't

✕
No large RCT has validated cognitive enhancement with oral MB in healthy adults; the only healthy-adult efficacy trial enrolled 26 participants 2.
Bronze
✕
An 891-patient Phase 3 RCT of LMTM (a stable MB derivative) found no significant slowing of cognitive or functional decline in mild-to-moderate Alzheimer's disease in the primary analysis 4.
Gold
✕
MB inhibits monoamine oxidase A; concurrent use with SSRIs, SNRIs, or other serotonergic drugs creates a documented risk of potentially fatal serotonin toxicity 3.
Safety-critical Gold
✕
Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency face risk of haemolytic anaemia from methylene blue and must not take it 3.
Safety-critical Silver
04The studies
Scored on Design quality Measurement precision Causal clarity Replication value
Gold Comprehensive review
Rojas et al. Progress in Neurobiology · 2012
First systematic review of MB's neurometabolic mechanisms, demonstrating that it functions as an electron cycler at mitochondrial Complex IV. Comprehensively reviews in vitro, animal, and early human evidence confirming memory-enhancing and neuroprotective effects at low doses. The mechanistic basis is well-supported; direct translation to healthy-adult oral supplementation remains extrapolative.
doi:10.1016/j.pneurobio.2011.10.007 Verify ↗
Silver
+7% memory retrieval improvement vs placebo (n=26)
Double-blind RCT · n=26
Rodriguez et al. Radiology · 2016
Low-dose MB (approximately 4 mg/kg) increased fMRI activity in bilateral insular cortex during sustained attention and prefrontal regions during short-term memory tasks. Memory retrieval improved by approximately 7% versus placebo. The n=26 sample limits generalisability; fMRI signal increases do not guarantee real-world cognitive benefit in larger or older populations.
doi:10.1148/radiol.2016152893 Verify ↗
Contested — n=26 is underpowered for definitive conclusions; fMRI signal increases do not guarantee real-world cognitive benefit in larger or older populations.
Gold
26 documented serotonin toxicity cases behind 2011 FDA warning
Mechanistic review and case analysis
Gillman Journal of Psychopharmacology · 2010
Demonstrates that MB is a potent MAO-A inhibitor. When co-administered with serotonergic drugs (SSRIs, SNRIs, tramadol, triptans), it precipitates serotonin toxicity. Twenty-six surgical case reports triggered the 2011 FDA drug safety communication; at least one was fatal. G6PD-deficient patients also face haemolysis risk. This is the definitive safety reference for MB drug interactions.
doi:10.1177/0269881109359098 Verify ↗
Gold
891 patients enrolled; no significant cognitive benefit in primary analysis
Phase 3 double-blind RCT · n=891
Gauthier et al. The Lancet · 2016
LMTM (leuco-methylthioninium), a stable MB derivative designed to inhibit tau aggregation, failed to slow cognitive or functional decline versus the 8 mg control dose in mild-to-moderate Alzheimer's disease. Primary analysis was unambiguously negative. A post-hoc monotherapy subgroup (n=136) showed a signal, but interpretation is contested due to the uncertain pharmacological inertness of the control.
doi:10.1016/s0140-6736(16)31275-2 Verify ↗
Contested — The control dose (8 mg twice daily) may not have been pharmacologically inert, complicating the null finding; post-hoc monotherapy subgroup benefit remains debated.
Silver
-70% approximate relative reduction in postoperative delirium vs control (n=248)
Open-label RCT · n=248
Deng et al. Journal of Clinical Anesthesia · 2021
Intraoperative IV methylene blue (2 mg/kg) in elderly patients undergoing major non-cardiac surgery reduced postoperative delirium by approximately two-thirds (7.3% vs 24.2% control) and early cognitive dysfunction by more than half (16.1% vs 40.2%). This was intravenous dosing in a surgical context; direct applicability to oral nootropic use in healthy adults is indirect.
doi:10.1016/j.jclinane.2020.110108 Verify ↗
05So what do you actually do

If the evidence interests you, a narrow, safe version is well-defined.

The human evidence supports only a cautiously scoped version.

01Rule out serotonergic drug interactions first: SSRIs, SNRIs, tramadol, and triptans all carry serotonin toxicity risk when combined with methylene blue.
02Test for G6PD deficiency before any trial; this enzyme deficiency makes methylene blue a haemolysis risk.
03Use only pharmaceutical-grade methylene blue; industrial or laboratory-grade material is not manufactured to ingestion-safety standards.
04Dose at the studied range (approximately 4 mg/kg as used in Rodriguez et al.); higher doses are associated with paradoxical cognitive impairment in animal models.
05Treat the evidence honestly: one n=26 RCT in healthy adults is the entire human efficacy base for oral cognitive enhancement.
06The verdict triad
Claim

The Mitochondrial Mechanism

Methylene blue functions as a genuine electron shuttle: it donates electrons directly to cytochrome c oxidase, bypassing dysfunctional upstream complexes and raising ATP output in neural tissue. The mechanism is confirmed in vitro and in animal models. Whether that translates to cognitive benefit in healthy humans is a separate question the evidence has only partly answered.

Consequence

A Mixed Evidence Record

The human evidence divides sharply. One n=26 healthy-adult RCT found a 7% memory-retrieval improvement. An 891-patient Phase 3 trial of a stable MB derivative found no cognitive benefit in Alzheimer's disease. IV dosing shows genuine neuroprotective effect in surgical settings, a result that does not translate directly to oral nootropic use.

Lever

Three Gates Before You Try

Before any self-experimentation: confirm G6PD status, rule out all serotonergic drugs (SSRIs, SNRIs, tramadol, triptans), and source pharmaceutical-grade product only. The studied oral dose in healthy adults was approximately 4 mg/kg; the human evidence base above that range is absent.

08What to do next
What to do next

Ready to optimise your cognitive baseline with evidence-graded protocols?

The HPC Cognitive Fuel Assessment maps your current cognitive performance and matches you to interventions with the strongest human-evidence ratings. Methylene blue is one of twelve compounds it evaluates.

Take the Cognitive Fuel Assessment
09Share & references
Update log
4 Jun 2026Initial publication; 5 sources reviewed, meta-analysis through 2021.
Related
Owning guide
The HPC Guide to Cognitive Fuel
Ranked protocols for sharpening attention, memory, and mental energy.
Read the guide →
Assessment
HPC Cognitive Fuel Assessment
Evidence-graded personalised protocol matching for cognitive performance.
Start assessment →
Trend Breakdown
Does Zone 2 Cardio Actually Sharpen Your Brain?
How aerobic exercise affects BDNF, hippocampal volume, and working memory.
Read the breakdown →
Bibliography · every source, resolvable
01Rojas, J.C., Bruchey, A.K. & Gonzalez-Lima, F. (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology, 96(1), 32-45. doi:10.1016/j.pneurobio.2011.10.007 Verify ↗Gold
02Rodriguez, P., Zhou, W., Barrett, D.W., Altmeyer, W., Gutierrez, J.E., Li, J., Lancaster, J.L., Gonzalez-Lima, F. & Duong, T.Q. (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology, 281(2), 516-526. doi:10.1148/radiol.2016152893 Verify ↗Silver
03Gillman, P.K. (2010). CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology, 25(3), 429-436. doi:10.1177/0269881109359098 Verify ↗Gold
04Gauthier, S., Feldman, H.H., Schneider, L.S., Wilcock, G.K., Frisoni, G.B., Hardlund, J.H., Moebius, H.J., Bentham, P., Kook, K.A., Wischik, D.J., Schelter, B.O., Davis, C.S., Staff, R.T., Bracoud, L., Shamsi, K., Storey, J.M.D., Harrington, C.R. & Wischik, C.M. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet, 388(10062), 2873-2884. doi:10.1016/s0140-6736(16)31275-2 Verify ↗Gold
05Deng, Y., Wang, R., Li, S., Zhu, X., Wang, T., Wu, J. & Zhang, J. (2021). Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open–label randomized controlled clinical trial. Journal of Clinical Anesthesia, 68, 110108. doi:10.1016/j.jclinane.2020.110108 Verify ↗Silver
Build better performance.
Get the 90-day protocol.